Kaitlyn Bader, Assistant Managing Editor

Christopher Bunick, MD, PhD, presented long-term safety data for JAK inhibitors upadacitinib and abrocitinib in atopic dermatitis at Fall Clinical 2026.

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic dermatographism, and her patient education podcast.

The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.

The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), discusses diagnosed prevalence of AD and care access findings from the NEA's State of AD 2026 report.

In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.

According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.

AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.

A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.

On this episode of Don't Be Rash, Andrew Krakowski, MD, spoke with Sheilagh Maguiness, MD, about the FDA's approval of bemotrizinol and what the new sunscreen filter means for pediatric patients.

Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.

The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.

The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.

Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.

On this episode of Don't Be Rash, Lisa Swanson, MD, joined host Andrew C. Krakowski, MD, to walk through the pediatric psoriasis treatment ladder, from first-line topicals to biologics and a new oral IL-23 blocker.

Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.

The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.

Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.

The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.

Victoria Werth, MD, professor of dermatology and rheumatology at the University of Pennsylvania, recently discussed brepocitinib's FDA approval for dermatomyositis and what the VALOR trial data mean for patients and clinicians.

At the Dermatology Times NP/PA Cutaneous Oncology Workshop in Tampa, Florida, Amit Om, MD, outlined why field-directed therapy is increasingly favored over lesion-directed treatment for actinic keratosis.

At the Dermatology Times NP/PA Connect Cutaneous Oncology Workshop in Tampa, Florida, Angad Chadha, MD, discussed his upcoming presentations on gene expression profiling and cutaneous side effects of immunotherapy.

As chair of the new Dermatology Times NP/PA Connect Cutaneous Oncology Workshop, Tristan Hasbargen, PA-C, discusses the program's curriculum and goals live in Tampa, Florida.

Victoria Werth, MD, reviews brepocitinib's boxed warning and expanded treatment options for dermatomyositis.

Victoria Werth, MD, discusses the FDA approval of brepocitinib for dermatomyositis and its supporting VALOR trial data.

Physicians' Education Resource and Dermatology Times debut a dedicated NP/PA education platform and a new congress series, opening with DermNexus this November in Scottsdale, Arizona.

Lisa Swanson, MD, joins Don't Be Rash host Andrew C. Krakowski, MD, for Psoriasis Awareness Month to discuss how pediatric psoriasis is often misdiagnosed and when it signals a heightened risk of psoriatic arthritis in kids.